StockData
Serina Therapeutics, Inc. logo

Serina Therapeutics, Inc. (SER) stock

SERNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$1.35−0.01 (-1.10%)

Close on Nov 18, 2026Market cap $34.29MP/E –Yield –

Serina Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Serina Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$21.20M. For fiscal 2025 it was -$18.01M. The highest annual figure on record is -$2.98M in fiscal 2023.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$18.01M–
FY2024Dec 31, 2024-$17.16M–
FY2023Dec 31, 2023-$2.98M–
FY2020Dec 31, 2020-$7.84M–
FY2019Dec 31, 2019-$10.80M–
FY2018Dec 31, 2018-$8.02M–
FY2017Dec 31, 2017-$6.29M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$6.71M–
Q1 FY2026Mar 31, 2026-$4.59M–
Q4 FY2025Dec 31, 2025-$6.03M–
Q3 FY2025Sep 30, 2025-$3.86M–
Q2 FY2025Jun 30, 2025-$3.80M–
Q1 FY2025Mar 31, 2025-$4.32M–
Q4 FY2024Dec 31, 2024-$4.59M-9107.8%
Q3 FY2024Sep 30, 2024-$2.97M–
Q2 FY2024Jun 30, 2024-$8.01M–
Q1 FY2024Mar 31, 2024-$1.59M–
Q4 FY2023Dec 31, 2023$51.00K–
Q3 FY2023Sep 30, 2023-$1.14M–
Q4 FY2020Dec 31, 2020-$1.62M–
Q3 FY2020Sep 30, 2020-$1.90M–
Q2 FY2020Jun 30, 2020-$2.25M–
Q1 FY2020Mar 31, 2020-$2.07M–
Q4 FY2019Dec 31, 2019-$2.71M–
Q3 FY2019Sep 30, 2019-$2.61M–
Q2 FY2019Jun 30, 2019-$2.87M–
Q1 FY2019Mar 31, 2019-$2.62M–
Q4 FY2018Dec 31, 2018-$2.05M–
Q3 FY2018Sep 30, 2018-$1.79M–
Q2 FY2018Jun 30, 2018-$2.17M–
Q1 FY2018Mar 31, 2018-$2.01M–

More Serina Therapeutics figures

See a number that looks wrong?